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A facile and efﬁcient synthesis of some
(6E)-hydroximino-4-en-3-one steroids, steroidal
oximes from Cinachyrella spp. sponges
Jianguo Cui , Liliang Huang , Lei Fan , Aimin Zhou
Introduction
A variety of steroids with unusual and interesting struc-
tures have been isolated from marine sponges, recently [1–3].
Among these steroidal compounds, marine steroids with
oxime groups have been reported rarely. In 1997, two steroidal
oximes, (6E)-hydroximino-24- ethylcholest-4-en-3-one (1) and
(6E)-hydroximinocholest-4-en-3-one (2), were isolated from
Cinachyrella alloclada and C. apion [4]. In 2005, another steroidal
oxime, (3E)-hydroximinocholest-4-en-6-one (3), was isolated
from Cinachyrella australiensis [5]. These steroids exert interest-
ing biological activities [6]. For example, bioassays showed that
compound 3 functions against hepatitis virus in vitro [5] and
compound 2 exhibitted a selective cytotoxic activity against
several types of cancer cells such as P-388, A-549, HT-29 (IC50:
1.25g/mL) andMEL-28 tumor cells (IC50: 2.5g/mL) [7]. In this
paper, a facile and efﬁcient synthetic method for the com-
pound 1, 2 and 4 is reported.
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Experimental
Chemistry
The sterol and NaBH4 were purchased from the Merck Co. All
chemicals and solvents were analytical grade and solvents
were puriﬁed by general methods before being used. Melt-
ing points were determined on an X4 apparatus and were
uncorrected. Infrared spectra were measured with a Nicolet
FT-360 Spectrophotometer. The 1H and 13CNMR spectra were
recorded in CDCl3 on a Bruker AV-500 spectrometer at working
frequencies 500 and 125MHz, respectively. Chemical shifts are
expressed in ppm (ı) values and coupling constants (J) in Hz.
LREIMS were recorded on a Thermo-DSQ instrument, while
HREIMS were measured on a Thermo-MAT95XP instrument.
The cell proliferation assay was undertaken by a MTS method
using 96-well plates onBeckmancoulter LD400AD/LDanalysis
spectrometer.
24-Ethylcholest-4-en-3,6-dione (6a)
Pyridinium chlorochromate (PCC) (2.564 g, 11.9mmol) was
added to a solution of sitosterol (5a) (0.852 g, 0.50mmol) in
dried CH2Cl2 (40mL) in one portion at room temperature. The
reactionwas completed in 26h. To themixturewas thenadded
30mL of CH2Cl2, and the suspension was poured over a sil-
ica gel column and eluted with CH2Cl2. The resulting solution
was washed with cold water and saturated brines. After dry-
ing over anhydrous sodium sulfate, the solvent was removed
under reduced pressure, and the resulting crude product was
puriﬁed by chromatography on silica gel using petroleum
ether (60–90 ◦C)/EtOAc (5:1) as eluent to give 0.75 g (86%) of
6a as pale yellow crystals, m.p. 172–174 ◦C. IR (KBr) : 2959,
1683, 1601, 1581, 1461, 1377, 1246, 1124, 948, 871 cm−1; 1H NMR
(500MHz, CDCl3): 0.724 (s, 3H, 18-CH3), 0.816 (d, 3H, J=7.0, 26-
or 27-CH3), 0.841 (d, 3H, J=7.0, 26- or 27-CH3), 0.848 (t, 3H,
J=8.0, 29-CH3), 0.935 (d, 3H, J=6.5, 21-CH3), 1.167 (s, 3H, 19-
CH3), 2.13–2.17 (m, 1H, C2-H), 2.44–2.58 (m, 2H, C7-H and
C2-H), 2.682 (dd, 1H, J=4.5, 15.5, C7-H), 6.170 (s, 1H, C4-H).
Cholest-4-en-3,6-dione (6b)
PCC (2.564 g, 11.87mmol) was added to a solution of choles-
terol (0.924 g, 2.2mmol) in dried CH2Cl2 (40mL) in one portion
at room temperature. The reaction was complete in 28h. The
workup similar to 6a provided 0.795 g (83.5%) of 6b as pale yel-
low crystals, m.p. 90–91 ◦C; IR(KBr) : 2953, 2865, 1693, 1600,
1486, 1249, 1221, 1117, 942 cm−1. 1H NMR (500MHz, CDCl3):
0.746 (s, 3H, 18-CH3), 0.886 (d, 3H, J=6.4, 26 or 27-CH3), 0.899
(d, 3H, J=6.4, 26 or 27-CH3), 0.952 (d, 3H, J=6.5, 21-CH3), 1.172
(s, 3H, 19-CH3), 2.546 (dd, 1H, J=5.2, 14.6, C2-H), 2.706 (dd, 1H,
J=4.0, 16.0, C7-H), 6.196 (s, 1H, C4-H).
Stigmast-4,22-dien-3,6-dione (6c)
6c was prepared similarly according to the procedure of 6a.
PCC (1.30 g, 6.0mmol) was added to a solution of stigmasterol
(0.50 g, 1.2mmol) in dried CH2Cl2 (10mL) in one portion at
room temperature. The reaction was complete in 27h. The
workup similar to 6a gave 0.42 g (83%) of 6c as pale yellow
crystals, m.p. 134–135 ◦C; IR(KBr): 2959, 1714, 1686, 1609, 969,
864 cm−1; 1HNMR (500MHz, CDCl3): 0.743 (s, 3H, 18-CH3), 0.805
(t, 3H, J=7.0, 29-CH3), 0.798 (d, 3H, J=6.5, 26- or 27-CH3), 0.849
(d, 3H, J=6.5, 26- or 27-CH3), 1.036 (d, 3H, J=7.0, 21-CH3), 1.169
(s, 3H, 19-CH3), 5.040 (dd, 1H, J=9.0, 15.2, C22-H), 5.150 (dd, 1H,
J=8.5, 15.2, C23-H), 6.171 (s, 1H, C4-H).
24-Ethylcholest-4-en-3ˇ-ol-6-one (7a)
NaBH4 (30mg, 0.79mmol) was added to a solution of 6a
(110mg, 0.25mmol) and CoCl2.6H2O (61mg, 0.26mmol) in
CH3OH (15mL) in the interval of 8min at room temperature.
After 15min, the reaction was stopped. The solution was neu-
tralized with 1M HCl. After evaporation of the majority of
the MeOH under reduced pressure, ethyl acetate (30mL) was
added to the residue. The resulting solution was washed with
cold water and saturated brines. After drying over anhydrous
sodium sulfate, the solvent was removed under reduced pres-
sure, and the resulting crude product was puriﬁed by ﬂash
chromatography on silica gel using petroleum ether/ethyl
acetate (2:1) as the eluent. The 7a was obtained as a white
solid (98mg, 87%), m.p. 140–141 ◦C; IR(KBr) : 3428, 2962, 2929,
2868, 1716, 1659, 1462, 1377, 1074, 968 cm−1; 1H NMR (CDCl3,
500MHz): 0.735 (s, 3H, 18-CH3), 0.839 (d, 3H, J=7.5, 26-CH3 or
27-CH3), 0.861 (d, 3H, J=7.5, 26-CH3 or 27-CH3), 0.869 (t, 3H,
J=8.0, 29-CH3), 0.943 (d, 3H, J=6.0, 21-CH3), 1.202 (s, 3H, 19-
CH3), 4.342 (m, 1H, C3-H), 6.193 (s, 1H, C4-CH).
Cholest-4-en-3ˇ-ol-6-one (7b)
Yield 88.2%, m.p. 125–126 ◦C; IR(KBr) : 3391, 2946, 2868, 1708,
1663, 1462, 1373, 1274, 1123, 1070, 960, 878 cm−1; 1H NMR
(CDCl3, 500MHz): 0.732 (s, 3H, 18-CH3), 0.882 (d, 3H, J=6.2, 26-
CH3 or 27-CH3), 0.895 (d, 3H, J=6.2, 26-CH3 or 27-CH3), 0.935 (d,
3H, J=6.5, 21-CH3), 1.184 (s, 3H, 19-CH3), 4.306 (m, 1H, C3-H),
6.193 (d, J=1.2, C4-H).
24-Ethylcholest-4,22-dien-3ˇ-ol-6-one (7c)
Yield 90%, m.p. 175–176 ◦C; IR(KBr) : 3457, 2954, 2860,
1711, 1659, 1458, 1385, 1279, 1074, 972 cm−1; 1H NMR(CDCl3,
500MHz): 0.730 (s, 3H, 18-CH3), 0.797 (d, 3H, J=6.5, 26-CH3 or
27-CH3), 0.848 (d, 3H, J=6.5, 26-CH3 or 27-CH3), 0.804 (t, 3H,
J=7.5, 29-CH3), 1.019 (d, 3H, J=6.5, 21-CH3), 1.184 (s, 3H, 19-
CH3), 4.329 (ddd, 1H, J=1.5, 5.5, 12.0, C3-H), 5.026 (dd, 1H,
J=8.5, 15.0, C22-H), 5.143 (dd, 1H, J=8.5, 15.0, C23-H), 6.167 (d,
1H, J=1.5, C4-H).
(6E)-Hydroximino-24-ethylcholest-4-en-3ˇ-ol (8a)
7a (150mg, 0.40mmol)was dissolved in 15mL 95%CH3CH2OH.
After the mixture was heated to 55 ◦C, CH3COONa·3H2O
(95mg, 0.70mmol) and NH2OH• HCl (60.6mg, 0.87mmol) were
added. The mixture was stirred at the temperature for 1.5h.
Then the reaction was terminated and the majority of sol-
vent was evaporated under reduced pressure. Proper water
was added into the reaction mixture, and the product was
extracted with ethyl acetate (3mL× 20mL). The combined
extracts were washed with saturated brine, dried, and evap-
orated under reduced pressure. The residue was subjected to
chromatography to give 109mg of 8a (70.3%), m.p. 91–92 ◦C;
IR(KBr) : 3428, 2958, 2933, 2868, 1634, 1462, 1377 cm−1; 1H
NMR(CDCl3, 500MHz): 0.722 (s, 3H, 18-CH3), 0.839 (d, 3H, J=7.0,
26-CH3 or 27-CH3), 0.861 (d, 3H, J=7.0, 26-CH3 or 27-CH3), 0.870
(t, 3H, J=8.0, 29-CH3), 0.940 (d, 3H, J=6.5, 21-CH3), 1.077 (s, 3H,
19-CH3), 3.064 (dd, 1H, J=3.0, 14.0, C7-H), 4.284 (ddd, 1H, J=1.0,
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3.5, 11.0, C3-H), 6.243 (s, 1H, C4-H); 13C NMR(CDCl3, 125MHz):
35.2 (1-C), 29.7 (2-C), 69.1 (3-C), 113.8 (4-C), 156.7 (5-C), 156.9 (6-
C), 28.1 (7-C), 33.9 (8-C), 53.6 (9-C), 41.7 (10-C), 21.4 (11-C), 39.7
(12-C), 42.5 (13-C), 56.1 (14-C), 23.1 (15-C), 26.2 (16-C), 55.8 (17-
C), 11.9 (18-C), 19.8 (19-C), 36.1 (20-C), 18.7 (21-C), 34.2 (22-C),
24.1 (23-C), 45.9 (24-C), 29.2 (25-C), 18.4 (26-C), 19.0 (27-C), 24.2
(28-C), 12.0 (29-C).
In the reaction, the 6Z-isomer 9a of 8a was obtained in 3%
yield, m.p. 119–121 ◦C; IR(KBr) : 3412, 2958, 2938, 2872, 1630,
1462, 1377, 1123, 911 cm−1; 1H NMR(CDCl3, 500MHz): 0.719 (s,
3H, 18-CH3), 0.839 (d, 3H, J=7.0, 26-CH3 or 27-CH3), 0.861 (d,
3H, J=7.0, 26-CH3 or 27-CH3), 0.869 (t, 3H, J=8.0, 29-CH3), 0.937
(d, 3H, J=6.0, 21-CH3), 1.109 (s, 3H, 19-CH3), 2.333-2.370 (m, 2H,
C7-H), 4.322 (dd, 1H, J=4.5, 12.0, C3-H), 6.922 (s, 1H, C4-H); 13C
NMR(CDCl3, 125MHz): 36.1 (1-C), 29.2 (2-C), 69.3 (3-C), 113.9 (4-
C), 153.7 (5-C), 160.5 (6-C), 29.7 (7-C), 33.9 (8-C), 53.8 (9-C), 39.6
(10-C), 21.2 (11-C), 39.4 (12-C), 42.0 (13-C), 56.0 (14-C), 24.2 (15-
C), 26.2 (16-C), 55.7 (17-C), 11.9 (18-C), 19.8 (19-C), 36.8 (20-C),
18.7 (21-C), 34.3 (22-C), 24.5 (23-C), 45.9 (24-C), 28.1 (25-C), 19.0
(26-C), 18.9 (27-C), 23.1 (28-C), 12.0 (29-C).
(6E)-Hydroximinocholest-4-en-3ˇ-ol (8b)
Yield 74.5%, m.p. 155–157 ◦C; IR(KBr) : 3374, 2949, 2864, 1629,
1462, 1376, 1315, 1119, 1070, 968, 890, 727, 674 cm−1; 1H
NMR(CDCl3, 500MHz): 0.717 (s, 3H, 18-CH3), 0.882 (d, 3H, J=2.0,
26-CH3 or 27-CH3), 0.895 (d, 3H, J=2.0, 26-CH3 or 27-CH3), 0.931
(d, 3H, J=6.5, 21-CH3), 1.070 (s, 3H, 19-CH3), 3.059 (dd, 1H, J=3.0,
14.0, C7-H), 4.273 (dd, 1H, J=4.4, 12.0Hz, C3-H), 6.249 (s, 1H,
C4-H).
In the reaction, the 6Z-isomer 9b of 8b was obtained in
4% yield, m.p. 124–126 ◦C; IR(KBr) : 3411, 2958, 2872, 1629,
1462, 1376 cm−1; 1H NMR(CDCl3, 500MHz): 0.762 (s, 3H, 18-
CH3), 0.894 (d, 3H, J=2.3, 26 or 27-CH3), 0.902 (d, 3H, J=2.3, 26
or 27-CH3), 0.965 (d, 3H, J=6.5, 21-CH3), 1.144 (s, 3H, 19-CH3),
4.277 (m, 1H, C3-H), 6.937 (d, 1H, J=2.1, C4-H).
(6E)-Hydroximino-24-ethylcholest-4,22-dien-3ˇ-ol
(8c)
Yield 69.1%, m.p. 96–97 ◦C; IR(KBr) : 3399, 2954, 2929, 2868,
1634, 1462, 1381, 1074, 968 cm−1; 1H NMR(CDCl3, 500MHz):
0.739 (s, 3H, 18-CH3), 0.822 (d, 3H, J=7.7, 26-CH3 or 27-CH3),
0.872 (d, 3H, J=7.0, 26-CH3 or 27-CH3), 0.829 (t, 3H, J=7.5, 29-
CH3), 1.040 (d, 3H, J=6.0, 21-CH3), 1.078 (s, 3H, 19-CH3), 3.064
(dt, 1H, J=3.5, 17.5, C7-H), 4.282 (ddd, 1H, J=2.0, 5.5, 12.5, C3-
H), 5.049 (dd, 1H, J=9.0, 15.0, C22-H), 5.172 (dd, 1H, J=8.5, 15.0,
C23-H), 6.247 (s, 1H, C4-H); 13C NMR(CDCl3, 125MHz): 35.2 (1-C),
29.7 (2-C), 69.0 (3-C), 113.9 (4-C), 156.7 (5-C), 156.9 (6-C), 28.8 (7-
C), 31.9 (8-C), 51.2 (9-C), 39.5 (10-C), 21.2 (11-C), 38.5 (12-C), 40.4
(13-C), 55.9 (14-C), 21.4 (15-C), 25.4 (16-C), 53.6 (17-C), 12.2 (18-
C), 18.7 (19-C), 41.6 (20-C), 19.0 (21-C), 138.1 (22-C), 129.5 (23-C),
42.4 (24-C), 34.2 (25-C), 21.1 (26-C), 18.4 (27-C), 24.3 (28-C), 12.1
(29-C).
In the reaction, the 6Z-isomer 9c of 8c was obtained in 3.5%
yield, m.p. 125–127 ◦C; IR(KBr): 3420, 2958, 2868, 1638, 1462,
1381, 1025, 976 cm−1; 1H NMR(CDCl3, 500MHz): 0.736 (s, 3H,
18-CH3), 0.820 (d, 3H, J=6.0, 26-CH3 or 27-CH3), 0.826 (t, 3H,
J=8.0, 29-CH3), 0.870 (d, 3H, J=6.0, 26-CH3 or 27-CH3), 1.036 (d,
3H, J=6.5, 21-CH3), 1.110 (s, 3H, 19-CH3), 4.323 (dd, 1H, J=4.0,
11.5, C3-H), 5.047 (dd, 1H, J=9.0, 14.5, C22-H), 5.168 (dd, 1H,
J=8.5, 14.5, C23-H), 6.922 (s, 1H, C4-H).
(6E)-Hydroximino-24-ethylcholest-4-en-3-one (1)
The Jones’ reagent of 0.5mL (0.267mol/L) was added drop-
wise to the solution of 8a (73mg, 0.164mmol) in 10mL of
acetone in 10min. The reaction mixture was stirred at room
temperature for 1h and then neutralized with 10% K2CO3
solution. The suspension was poured over a silica gel col-
umn and eluted with ethyl acetate. The solvent was removed
under reduced pressure. The residue was chromatographed
on silica gel using petroleum ether (60–90 ◦C)/EtOAc (3:1) as
eluent to give 46mg (63%) of 1, m.p. 197–198 ◦C; IR(KBr) : 3383,
2958, 2933, 2868, 1704, 1659, 1585, 1462, 1377, 1250, 984 cm−1;
1H NMR(CDCl3, 500MHz): 0.737 (s, 3H, 18-CH3), 0.839 (d, 3H,
J=6.5, 26-CH3 or 27-CH3), 0.861 (d, 3H, J=6.5, 26-CH3 or 27-
CH3), 0.868 (t, 3H, J=8.5, 29-CH3), 0.956 (d, 3H, J=6.5, 21-CH3),
1.064 (s, 3H, 19-CH3), 2.274 (ddd, 1H, J=5.0, 14.0, 18.5, C7-
H), 2.662 (dd, 1H, J=4.0, 16.5, C2–H), 3.097 (dd, 1H, J=3.5,
18.5, C7-H), 6.778 (s, 1H, C4-H), 8.917 (brs, 1H, N-OH); 13C
NMR(CDCl3, 125MHz): 36.1 (1-C), 33.4 (2-C), 200.9 (3-C), 126.3
(4-C), 155.8 (5-C), 149.2 (6-C), 26.0 (7-C), 33.4 (8-C), 50.0 (9-C),
42.5 (10-C), 21.3 (11-C), 39.3 (12-C), 46.0 (13-C), 56.7 (14-C), 24.0
(15-C), 28.0 (16-C), 55.9 (17-C), 11.9 (18-C), 18.9 (19-C), 38.9 (20-
C), 18.7 (21-C), 33.9 (22-C), 26.1 (23-C), 45.9 (24-C), 29.2 (25-C),
19.8 (26-C), 19.0 (27-C), 23.1 (28-C), 12.0 (29-C); LREIMS (70 eV,
m/z %): 441 (M+, 26), 426 (M+-CH3, 100), 424 (M+-OH, 35), 152
(38), 127 (89); HREIMS:m/z 441.3604 [M]+ (calcd for C29H47O2N1,
441.3601).
(6E)-Hydroximinocholest-4-en-3-one (2)
Yield 61%, m.p. 188–191 ◦C; IR(KBr) : 3738, 3281, 2942, 2868,
1716, 1659, 1581, 1471, 1381, 1250, 1283, 1172, 1127, 1078, 1029,
980, 927, 866, 788, 735 cm−1; 1H NMR(CDCl3, 500MHz): 0.734
(s, 3H, 18-CH3), 0.884 (d, 3H, J=6.2, 26-CH3 or 27-CH3), 0.897
(d, 3H, J=6.2, 26-CH3 or 27-CH3), 0.942 (d, 3H, J=6.5, 21-CH3),
1.159 (s, 3H, 19-CH3), 2.274 (ddd, 1H, J=5.0, 14.0, 18.5, C7-H),
2.519 (dd, 1H, J=5.1, 14.7, C2-H), 3.437 (dd, 1H, J=4.6, 15.9, C7-
H), 6.338 (s, 1H, C4-H), 9.033 (brs, 1H, N-OH); 13C NMR(CDCl3,
125MHz): 36.1 (1-C), 33.5 (2-C), 200.9 (3-C), 126.3 (4-C), 155.7 (5-
C), 149.2 (6-C), 28.0 (7-C), 33.3 (8-C), 50.0 (9-C), 42.5 (10-C), 21.3
(11-C), 39.5 (12-C), 46.0 (13-C), 56.7 (14-C), 24.0 (15-C), 28.1 (16-
C), 56.0 (17-C), 11.9 (18-C), 18.9 (19-C), 35.7 (20-C), 18.7 (21-C),
38.9 (22-C), 23.8 (23-C), 39.3 (24-C), 28.0 (25-C), 22.8 (26-C), 22.5
(27-C); LREIMS (70 eV, m/z %): 413 (M+, 79), 396 (M+-OH, 100),
395 (M+-H2O, 30), 152(93); HREIMS: m/z 413.3289 [M]+ (calcd for
C27H43O2N1, 413.3288).
(6E)-Hydroximino-24-ethylcholest-4,22-dien-3-one
(4)
Yield 60%, m.p. 185–187 ◦C; IR(KBr) : 3371, 2958, 2868,
1708, 1679, 1581, 1458, 1377, 1242, 976 cm−1; 1H NMR(CDCl3,
500MHz): 0.759 (s, 3H, 18-CH3), 0.833 (t, 3H, J=7.5, 29-CH3),
0.826 (d, 3H, J=6.5, 26-CH3 or 27-CH3), 0.875 (d, 3H, J=6.5,
26-CH3 or 27-CH3), 1.061 (d, 3H, J=8.5, 21-CH3), 1.069 (s, 3H,
19-CH3), 2.274 (ddd, 1H, J=5.5, 14.5, 18.0, C7-H), 2.657 (dd, 1H,
J=3.0, 16.0, C2-H), 3.097 (dd, 1H, J=5.0, 18.0, C7-H), 5.065 (dd,
1H, J=9.0, 15.5, C22-H), 5.181 (dd, 1H, J=8.5, 15.5, C23-H), 6.779
(s, 1H, C4-H); 13C NMR(CDCl3, 125MHz) ı: 38.9 (1-C), 33.5 (2-C),
200.9 (3-C), 126.3 (4-C), 155.8 (5-C), 149.1 (6-C), 28.7 (7-C), 31.9
(8-C), 51.3 (9-C), 42.4 (10-C), 21.3 (11-C), 39.2 (12-C), 46.0 (13-C),
56.8 (14-C), 24.1 (15-C), 31.8 (16-C), 55.9 (17-C), 12.2 (18-C), 18.9
(19-C), 40.4 (20-C), 21.1 (21-C), 137.9 (22-C), 129.7 (23-C), 50.1
254
(24-C), 33.3 (25-C), 21.2 (26-C), 18.7 (27-C), 25.4 (28-C), 12.1 (29-
C); LREIMS (70 eV, m/z %): 439 (M+, 100), 422 (M+-OH, 45), 396
(M+-CH(CH3)2, 89), 298(59), 152(87); HREIMS: m/z 439.3445 [M]+
(calcd for C29H45O2N1, 439.3445).
The similar method was used for synthesizing the com-
pounds 2 and 4. Therefore, only experimental details for the
synthesis of compound 1 are reported.
Antiproliferative activity
Materials and methods
Stock solutions of compounds 1, 2 and 4, were prepared in
sterile dimethyl sulfoxide (DMSO) (Sigma) at a concentration
of 10mg/mL and afterwards diluted with complete nutrient
medium (RPMI-1640) supplementedwith 10%heat inactivated
fetal bovine serum and 0.1 g/L penicillin G+0.1 g/L strepto-
mycin sulfate.
Cell culture
Sk-Hep-1, H-292, PC-3 (ATCC) and Hey-1B (a gift from Dr. Yan
Xu, University of Indiana) cells were cultured in a proper
medium supplemented with 10% fetal bovine serum in a
humidiﬁed atmosphere of 5% CO2 at 37 ◦C.
Treatment of cancer cells
Cancer cells (4× 103 cells/200L) were seeded into eachwell of
a 96-well microtiter plate. After incubation for 24h, the com-
pounds with a series of concentrations (range 20–80g/mL)
were added to the cells. An equal amount of DMSO was added
to the cells used as negative controls. All were treated in trip-
licate.
Determination of cell viability
MT Stetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
(CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay,
Cat.# G5421, Promega Corporation) dye reduction assay was
used. The assay is dependent on the MTS being reduced to
an aqueous, soluble formazan by dehydrogenase enzymes
found in metabolically active cells. The quantity of formazan
product as measured by the amount of 490nm absorbance is
directly proportional to the number of living cells in culture.
Brieﬂy, after treatment (see Section2.2.3) for 72h, the medium
was removed and the cells were incubated with 100L of
fresh medium plus 20L of MTS solution according to the
instruction for additional 4h. The absorbance (A) at 490nm
was measured using an Beckman coulter LD400AD/LD anal-
ysis spectrometer. IC50 concentration was deﬁned as the
concentration of an agent inhibiting cell survival by 50%,
compared to a control.
Results and discussion
The initial studies for the synthesis of this kind of oxime-
steroid system were based on the methodology developed by
Holland et al. [8]. Seven steps were needed to synthesize com-
pound 1 as reported in reference [4]. Later Kovganko et al.
reported two new synthesis routes for the compound 1, both
were rather complicated and the overall yields were relatively
low [9,10]. Here, we introduce a new synthetic method for the
steroidal oxime compound 1, 2 and 4withhigher overall yields
and fewer synthetic steps. For example, using -sitosterol as
raw material, four steps are needed for synthesizing the com-
pound 1 with an overall yield of 33%. The synthesis route of
the compound 1, 2 and 4 is as shown in Fig. 1.
Fig. 1 – The synthesis of some (6E)-hydroximino-4-en-3-one steroids. (a) PCC/C H2Cl2; (b) NaBH4/CH3OH, CoCl2·6H2O;
(c) NaAc·3H2O/95% C2H5OH, H2OH·HCl; (d) Jones agent/acetone.
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Table 1 – In vitro antitumor activities (IC50 g/mL) of 1, 2
and 4a
Compound Sk-Hep-1 H-292 PC-3 Hey-1B
1 ≥80 ≥80 ≥80 ≥80
2 33 32.6 35 54
4 43 59.5 44 37
a MTS method was used to assay of antiproliferative activity.
In step1, -sitosterol (5a) is transformed into the cor-
responding 24-ethylcholest-4-en-3,6-dione (6a) via oxidation
with PCC in CH2Cl2 in 86% yield. Selective reduction of 6a by
NaBH4 in the presence of CoCl2 gives 24-ethylcholest-4-en-3-
ol-6-one (7a) in 85% yield according to the synthetic method
we developed [11]. The structure of 7a was conﬁrmed by com-
paring IR and 1H NMR spectra with those of the analogous
compound that was synthesized previously in Ref. [12].
Next, the oxime 8a is obtained by the reaction of 7a with
hydroxylamine hydrochloride in ethanol in the presence of
NaOAc in 75% yield. The structure of 8awas proved by spectral
data. At the same time, cis-isomer 9a of 8a was obtained in
9.5% yield.
Oxidation of 8a by Jones’ reagent in acetone gives the target
steroid 1 in 69% yield. The IR and 1H NMR spectra data of 1 are
perfectly consistent with those of the natural compound 1.
The compound 2 and 4 were prepared in the similar syn-
thetic method to the compound 1.
To determine the biological activity of these compounds,
we investigated their ability against four human tumor cell
lines: Sk-Hep-1 (human liver carcinoma), H-292 (human lung
carcinoma), PC-3 (human prostate carcinoma) and Hey-1B
(human ovarian carcinoma). The results, expressed as IC50
values in g/mL, are reported in Table 1.
Our results showing in the Table 1 revealed that the
compound 2 and 4 displayed a modest cytotoxic activ-
ity against these cancer cells. Interestingly the structure
of side chains on these steroidal oximes plays an impor-
tant role in their cytotoxicity. The antineoplastic activity of
these compounds increases along with the order of the side
chain attached: cholesterol-like side chain(2) > stigmasterol-
like side chain(4) > sitosterol-like side chain(1). The presence
of a cholesterol-type side chain appears to be necessary for the
biological activity. This is consistwith the conclusion obtained
by Rodrı´guez et al. [7].
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